Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/valsartan - Novartis

Drug Profile

Amlodipine/valsartan - Novartis

Alternative Names: Amlodipine 10mg/Valsartan 160mg; Amlodipine besilate/valsartan; Amlodipine besylate/valsartan; Dafiro; Exforge; EXPO-G-Tab; ID1803; VAA489; Valsartan/amlodipine

Latest Information Update: 06 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Ischaemic heart disorder therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 04 Dec 2019 IlDong Pharmaceutical plans a phase I pharmacodynamics/pharmacokinetic interaction and safety study in Healthy volunteers (ID-VARE-101; NCT04185090)
  • 28 Aug 2019 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Korea (PO, Tablet)
  • 22 May 2019 Kyung Dong Pharmaceutical completes the phase I KD5001 trial in Hypertension (In volunteers) in South Korea (PO) (KCT0001660)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top